8-KOther Events

PFIZER INC 8-K Report, Corporate Update (Jun 26, 2020)

Filed June 26, 2020For Securities:PFE

Summary

This 8-K filing from Pfizer Inc. (PFE) on June 26, 2020, primarily details significant debt offerings by its wholly-owned subsidiary, Upjohn Inc. (Newco), and its financing subsidiary, Upjohn Finance B.V. (Finco). These offerings total $1.0 billion to $2.0 billion in U.S. Dollar Senior Notes across various maturities and €750 million to €1.25 billion in Euro Senior Notes. The proceeds from these notes are intended to fund a substantial $12 billion cash payment to Pfizer as partial consideration for the separation of Pfizer's Upjohn Business, paving the way for its combination with Mylan N.V. Investors should note that these debt issuances are integral to the planned separation and combination, representing a material financial transaction to facilitate the spin-off of the Upjohn business. The filing also outlines the terms of these debt instruments, including their senior unsecured nature and initial guarantees from Pfizer, which are set to terminate upon the completion of the distribution. Post-combination, Mylan entities are expected to become guarantors of these notes. This move signals a significant restructuring for Pfizer, isolating its established medicines business into a new entity that will merge with Mylan, and raising substantial capital to support this strategic maneuver. Investors should closely monitor the progress and implications of this combination and the resulting financial structure of the new entity.

Key Highlights

  • 1Upjohn Inc. (Newco) and its financing subsidiary Finco completed multiple senior note offerings totaling $7.75 billion and €3.80 billion in aggregate principal amounts.
  • 2The U.S. Dollar Notes range from 1.125% due 2022 to 4.000% due 2050, with principal amounts between $750 million and $2.0 billion per issuance.
  • 3The Euro Notes range from 0.816% due 2022 to 1.908% due 2032, with principal amounts between €750 million and €1.25 billion per issuance.
  • 4Proceeds from these debt offerings, along with other financing, will fund a $12 billion cash payment to Pfizer as partial consideration for the Upjohn Business contribution.
  • 5These debt issuances are directly linked to the proposed combination of Pfizer's Upjohn Business with Mylan N.V.
  • 6The notes are senior unsecured obligations, initially guaranteed by Pfizer, with guarantees set to terminate upon the completion of the distribution of Newco shares.
  • 7Mylan entities are expected to become guarantors of these notes post-combination.

Frequently Asked Questions

The primary purpose of these debt offerings by Upjohn Inc. (Newco) and Upjohn Finance B.V. (Finco) is to raise capital to fund a $12 billion cash payment to Pfizer Inc. This payment is part of the consideration for Pfizer contributing its Upjohn Business to Newco, in preparation for its combination with Mylan N.V.

The U.S. Dollar Notes are senior unsecured obligations of Upjohn Inc. (Newco), and the Euro Notes are senior unsecured obligations of Upjohn Finance B.V. (Finco). Initially, Pfizer Inc. provided guarantees for both series of notes, but these guarantees will terminate upon the completion of the distribution. Following the combination with Mylan, Mylan entities are expected to become guarantors of these notes.

These debt offerings are a crucial financing component for the proposed business combination between Pfizer's Upjohn Business and Mylan N.V. The funds raised will facilitate the separation of the Upjohn Business from Pfizer and its subsequent merger with Mylan, creating a new, larger pharmaceutical company.

The risks are tied to the success of the Upjohn/Mylan combination. Factors include regulatory approvals, integration challenges, Mylan shareholder approval, potential loss of business or customers, and the ability of the combined entity to achieve expected financial performance and synergies. The notes are unsecured obligations, meaning bondholders rank behind secured creditors in the event of bankruptcy. The forward-looking statements section of the filing outlines numerous specific risks.